Safety in terms of adverse cardiovascular events and all-cause mortality associated with xanthine oxidase inhibitors versus non-xanthine oxidase inhibitors and comparison between allopurinol and febuxostat in patients with gout: A retrospective cohort study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allopurinol (Primary) ; Febuxostat (Primary) ; Xanthine oxidase inhibitors (Primary)
Indications Gout
Focus Adverse reactions

Most Recent Events

03 Jan 2020 New trial record
24 Dec 2019 Results published in the Rheumatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight